



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Pierre J-M Riviere et al.
Title: TREATMENT OF BONE
METASTASES BY MEANS OF
PTH RECEPTOR AGONISTS
Appl. No.: 10/587,184
International Filing Date: January 13, 2005
Examiner: Unassigned
Art Unit: Unassigned
Conf. No.: 6577

TRANSMITTAL OF RESPONSE TO NOTICE TO COMPLY

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications
Containing Nucleotide and/or Amino Acid Sequence Disclosures, mailed February 5, 2007,
in the above-identified application, transmitted herewith are the following documents:

Enclosed are:

- [X] Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§
1.821-1.825 (1 page).
- [X] Copy of Sequence Listing (23 pages).
- [X] Return Copy of Notice to Comply (2 pages).
- [X] Computer Readable Format (CRF), (1 diskette).

Additional Fees are calculated below:

	Claims as Filed		Included in Basic Fee		Extra Claims		Rate		Fee Totals
Basic Filing Fee, Search Fee & Examination Fee							\$1,000.00		\$0.00
Size Fee	72	-	100	=	0	x	\$250.00	=	\$0.00
Total	20	-	20	=	0	x	\$50.00	=	\$0.00
Claims:									
Independents:	2	-	3	=	0	x	\$200.00	=	\$0.00
If any Multiple Dependent Claim(s) present:						+	\$360.00	=	\$0.00
Surcharge under 37 CFR 1.16(f) for late filing of Executed Declaration and late payment of filing fee						+	\$130.00	=	\$0.00
Extension fee for response filed within the first month:						+	\$120.00	=	\$0.00
							SUBTOTAL:	=	\$0.00
[] Small Entity Fees Apply (subtract ½ of above):								=	
							TOTAL FILING FEE:	=	\$0.00
Processing Fee under 37 CFR 1.17(i) for Late Filing of English Translation of Application:						+	\$130.00	=	\$0.00
							TOTAL FEE	=	\$0.00

The Commissioner is hereby authorized to charge any fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment form being unsigned, providing incorrect information resulting in a rejected credit card transaction, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

If any extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Respectfully submitted,

Date: March 15, 2007

By: Courtenay C. Brinckerhoff

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5300
Facsimile: (202) 672-5399

Courtenay C. Brinckerhoff
Attorney for Applicants
Registration No. 37,288



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/587,184	Pierre J-M Riviere	052209-0150

INTERNATIONAL APPLICATION NO.

PCT/US05/01139

I.A. FILING DATE	PRIORITY DATE
01/13/2005	01/26/2004

22428
 FOLEY AND LARDNER LLP
 SUITE 500
 3000 K STREET NW
 WASHINGTON, DC 20007

CONFIRMATION NO. 6577

371 FORMALITIES LETTER



OC000000022327247

Date Mailed: 02/05/2007

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed

to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://portal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

KAREN M WILLIAMS

Telephone: (703) 308-9140 EXT 213

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/587,184	PCT/US05/01139	052209-0150

FORM PCT/DO/EO/922 (371 Formalities Notice)